|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM232469628 |
| 003 |
DE-627 |
| 005 |
20231224093043.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.09.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0775.xml
|
| 035 |
|
|
|a (DE-627)NLM232469628
|
| 035 |
|
|
|a (NLM)24211844
|
| 035 |
|
|
|a (PII)S1521-6616(13)00244-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jang, Young-Soon
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a CD27 engagement by a soluble CD70 protein enhances non-cytolytic antiviral activity of CD56bright natural killer cells by IFN-γ secretion
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.12.2013
|
| 500 |
|
|
|a Date Revised 02.01.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2013.
|
| 520 |
|
|
|a We investigated regulation of human NK cell function by CD27 engagement using a recombinant soluble CD70 protein. CD27 was preferentially expressed on CD56(bright) NK cells, and soluble CD70 protein bound to CD27(+)CD56(bright) NK cells. While soluble CD70 protein enhanced IFN-γ secretion by CD56(bright) NK cells in the presence of IL-12, it augmented neither cytolytic activity nor proliferation of NK cells. Thus, we next asked if soluble CD70 protein could be used to induce non-cytolytic antiviral activity of NK cells using an in vitro hepatitis C virus (HCV) infection system. Soluble CD70 protein stimulated NK cells to suppress HCV replication by enhancing NK cell IFN-γ secretion without killing infected cells. Taken together, we demonstrate that CD27 engagement by a soluble CD70 protein enhances non-cytolytic antiviral activity of CD56(bright) NK cells by IFN-γ secretion. Thus, this soluble CD70 protein may be useful for the treatment of viral infections such as HCV infection
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a CD27
|
| 650 |
|
4 |
|a CD70
|
| 650 |
|
4 |
|a Hepatitis C virus
|
| 650 |
|
4 |
|a IFN-γ
|
| 650 |
|
4 |
|a Natural killer cells
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a CD27 Ligand
|2 NLM
|
| 650 |
|
7 |
|a CD56 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD70 protein, human
|2 NLM
|
| 650 |
|
7 |
|a NCAM1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Proteins
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor Receptor Superfamily, Member 7
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-12
|2 NLM
|
| 650 |
|
7 |
|a 187348-17-0
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Kang, Wonseok
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chang, Dong-Yeop
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sung, Pil Soo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Bum-Chan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yoo, Seok Ho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Young Woo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shin, Eui-Cheol
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 3 vom: 03. Dez., Seite 379-87
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:3
|g day:03
|g month:12
|g pages:379-87
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.09.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 149
|j 2013
|e 3
|b 03
|c 12
|h 379-87
|